# Why High Lp(a) Levels Fuel Ongoing Heart Risks

## Summary
A new study of over 20,000 adults from NIH trials links Lp(a) levels ≥175 nmol/L to higher risks of stroke and cardiovascular death, especially in those with existing heart disease, independent of LDL control. No association with heart attacks was found. Lp(a), genetically driven and similar to LDL but with clotting factors, contributes to residual risk despite standard treatments. Experts recommend universal testing and aggressive risk factor management.

## Content
High Lipoprotein(a) Levels Linked to Persistent Cardiovascular Risk

            
              
              
                Lab analysis of blood for cardiovascular risk factors like Lp(a)  (Credit: Polina Tankilevitch via Pexels)
              
            
A new study suggests elevated lipoprotein(a)—or Lp(a)—levels are linked to residual cardiovascular risk, including higher odds of stroke and cardiovascular death, even among people on standard treatments.

High Lp(a) levels were linked to significantly increased risk of major cardiovascular events, including stroke and cardiovascular death.
The association was strongest in those with existing cardiovascular disease, suggesting Lp(a) contributes to ongoing risk even with standard treatment.
No clear link was found between elevated Lp(a) and heart attack risk.
The findings support Lp(a) as an important, largely genetic risk factor that could help improve cardiovascular risk assessment.

Understanding Lipoprotein(a)

            
              
              
                Structure of Lp(a), a cholesterol particle with clotting proteins  (Credit: Polina ⠀ via Pexels)
              
            
Lipoprotein(a) is a cholesterol-carrying particle similar to low-density lipoprotein (LDL), or “bad” cholesterol. Unlike LDL, Lp(a) contains proteins that promote blood clotting, potentially making it a greater cardiovascular risk factor. Source: NHLBI.
Lp(a) contributes to residual cardiovascular risk—the risk of events despite lowered LDL. Levels are largely genetic, with 70–90% determined by the LPA gene. About 1 in 5 people have elevated levels. Source: AHA.
Study Details and Key Findings

            
              
              
                Participants in NIH trials like ACCORD, PEACE, and SPRINT  (Credit: DS stories via Pexels)
              
            
Researchers analyzed data from 20,070 adults aged 40+ (average age ~65 years, ~65% male) in three NIH trials: ACCORD, PEACE, and SPRINT. For related diabetes management insights, see Ozempic Revolutionizing Obesity Treatment?.
Participants were grouped by Lp(a) levels: low (<75 nmol/L) to very high (≥175 nmol/L), and prior cardiovascular disease status. Over ~4 years median follow-up, 7.3% experienced major adverse cardiovascular events (MACE: heart attack, stroke, CV death). Learn more about obesity-related risks in GLP-1s Cut Asthma Attacks 14% in Overweight Patients.
Individuals with Lp(a) ≥175 nmol/L had significantly higher risk of stroke and CV death, especially with existing CVD. No association with heart attack risk. CDC Heart Risk Factors.

“We would generally consider a Lp(a) level of over 125 nmol/L to be high. The threshold of ≥175 nmol/L identified in the study would be considered extremely high and should drive aggressive management of other cardiovascular risk factors.”
— Cheng-Han Chen, MD, interventional cardiologist, MemorialCare Saddleback Medical Center. Source.

Findings were presented at the SCAI 2026 Scientific Sessions and CAIC-ACCI Summit in Montreal. Abstract. FDA Cardiovascular Devices.
Implications for Screening and Management

            
              
              
                Discussing Lp(a) screening and risk management strategies  (Credit: Markus Winkler via Pexels)
              
            
Lp(a) testing is simple and inexpensive. Experts recommend testing at least once in adulthood to assess risk, particularly for those with family history or prior events. Mayo Clinic Cholesterol Testing.
For elevated levels, strategies include aggressive LDL lowering, blood pressure and diabetes control, lifestyle changes (exercise, heart-healthy diet low in sodium/saturated fat, no tobacco/alcohol), and closer monitoring.
Emerging therapies targeting Lp(a) are in development. Further research is needed for subgroups like those with kidney or peripheral artery disease. National Kidney Foundation Heart Disease.
Lp(a) measurement could enhance routine risk assessment, especially for residual risk despite LDL control. Source: AHA Journals; Source: Nature.
References:

NHLBI: Lipoprotein(a) - What to Know About Elevated Levels
NCBI: LPA Gene
AHA: Lipoprotein(a)
ACCORD Trial
PEACE Trial
SPRINT Study
MemorialCare: Cheng-Han Chen, MD
SCAI 2026 Abstract
AHA Journals
Nature: Scientific Reports
CDC: Heart Disease Risk Factors
FDA: Cardiovascular Devices
Mayo Clinic: Cholesterol Test
National Kidney Foundation: Heart Disease
Sources:Original Source

---
Source: Kodawire (EN)